Table 2.
Patient demographics (N = 266)
| No-GVHD (n = 131) | Non-GI (n = 29) | UGI (n = 53) | LGI (n = 53) | P value | |
|---|---|---|---|---|---|
| Median age (range), y | 57 (24-77) | 53 (23-72) | 55 (23-74) | 53 (21-78) | .378 |
| Male sex, no. (%) | 98 (75) | 17 (59) | 29 (52) | 27 (51) | .004 |
| Diagnosis, no. (%) | |||||
| Acute leukemia/MDS | 54 (41) | 20 (69) | 34 (64) | 25 (47.2) | .004 |
| Lymphoma/CLL/LGL/T-PLL | 74 (57) | 8 (28) | 17 (32) | 23 (43.4) | |
| CML/MM | 3 (2) | 1 (3) | 2 (4) | 5 (9.4) | |
| Conditioning regimens | |||||
| Myeloablative and reduced intensity, no. (%) | .003 | ||||
| TBI-based∗ | 40 (30.5) | 12 (41) | 29 (54.7) | 26 (49) | |
| Chemotherapy-based† | 40 (30.5) | 12 (41) | 29 (54.7) | 26 (49) | |
| Nonmyeloablative, no. (%) | 57 (43.5) | 13 (45) | 20 (37.7) | 23 (43) | |
| Cy/Flu/TBI 200 cGy | 34 (26) | 4 (14) | 4 (7.6) | 4 (8) | |
| Donor, no. (%) | |||||
| MRD | 52 (40) | 2 (7) | 11 (21%) | 5 (9.4%) | <.001 |
| MUD/MMUD | 43/3 (35) | 11/- (38) | 11/1 (22.5) | 18/5 (43.3) | |
| Haploidentical | 7 (5) | 4 (14) | 3 (5.5) | 2 (4) | |
| Cord blood | 26 (20) | 12 (41) | 27 (51) | 23 (43.3) | |
| Donor-recipient HLA-match, no. (%) | |||||
| 8/8 | 97 (74) | 13 (45) | 23 (43) | 23 (43.5) | <.001 |
| 7/8 | 3 (2) | 2 (7) | 1 (2) | 5 (9.5) | |
| <7/8 | 31 (24) | 14 (48) | 29 (55) | 25 (47) | |
| Stem cell source, no. (%) | |||||
| BM | 12 (9) | 3 (10.3) | 6 (11) | 3 (6) | <.001 |
| PBSC | 93 (71) | 14 (48.3) | 20 (38) | 27 (51) | |
| Cord blood‡ | 26 (20) | 12 (41.4) | 27 (51) | 23 (43) | |
| GVHD prophylaxis, no. (%) | |||||
| CNI/MTX/ ± siro ± other§ | 96 (73) | 13 (45) | 22 (39) | 24 (45) | <.001 |
| CSA/MMF | 26 (20) | 12 (41) | 29 (52) | 23 (43.5) | |
| PTCy based | 9 (7) | 4 (14) | 5 (9) | 6 (11.5) | |
| GVHD severity, no. (%) | |||||
| Grade I | - | 11 (38) | - | - | <.001 |
| Grade II | - | 7 (24) | 50 (94) | 32 (60) | |
| Grade III | - | 11 (38) | 3 (6) | 10 (19) | |
| Grade IV | - | - | - | 11 (21) |
P values compare the distribution of covariates (rows) across all cohorts with the exception of GVHD severity, which only includes those with GVHD and were obtained using a Fisher exact test for categorical variables and Kruskal-Wallis for age as a continuous variable.
BM, bone marrow; CLL, chornic lymphocytic leukemia; CNI, calcineurin inhibitor; CML, chronic myeloid leukemia; CSA, cyclosporine-A; HLA, human leukocyte antigen; LGL, large granular lymphocytic;MA, myeloablative; MDS, myelodysplastic syndrome; MM, multiple myeloma; MMF, mycophenolate mofetil; MMUD, mismatched-unrelated donor; MRD, matched-related donor; MTX, methotrexate; MUD, matched-unrelated donor; N/A, not applicable; NMA, non-myeloablative; PBSC, peripheral blood stem cell; PTCy, post-transplant cyclophosphamide; RI, reduced intensity; siro, sirolimus; TBI, total body irradiation; T-PLL, T-cell prolymphocytic leukemia.
Includes cyclophosphamide/TBI 1375 cGy, fludarabine/TBI 1375 cGy, cyclophosphamide/thiotepa/TBI 1375 cGy, fludarabine/cyclophosphamide/TBI 1320 to 1375 cGy, cyclophosphamide/fludarabine/thiotepa/TBI 400 cGy.
Includes melphalan/fludarabine, fludarabine/busulfan, melphalan/thiotepa/fludarabine, busulfan/melphalan, busulfan/fludarabine/cyclophosphamide, clofarabine/thiotepa /melphalan, busulfan/cyclophosphamide.
Includes 33 patients who received cord blood graft combined with a haploidentical ex vivo CD34+ selected T-cell depleted graft as a myeloid bridge as part of protocol (NCT01682226).
Other includes bortezomib, maraviroc, and mycophenolate mofetil. Five patients did not receive methotrexate but tacrolimus/sirolimus/MMF (n = 1), tacrolimus/MMF (n = 2), and tacrolimus/sirolimus (n = 2).